Company Overview

Rubicon Research Limited (formerly Rubicon Research Private Limited) reported strong FY2025-26 financial performance, marking its first year as a public company following a successful ₹13,775 million IPO completed in October 2025. The company operates in the pharmaceutical sector with significant presence in US markets.

Financial Performance Highlights

Consolidated Results (FY26 vs FY25):

  • Revenue from Operations: ₹17,540 million (36.6% YoY growth)
  • Operating EBITDA: ₹4,002 million (52.3% YoY growth)
  • EBITDA Margin: 22.8%
  • Profit After Tax: ₹2,467 million (83.6% YoY growth)
  • R&D Expenditure: ₹1,989 million (11.34% of revenue)
  • Return on Average Capital Employed: 36% (pre-tax)
  • Units Sold: ~5.05 billion+

Standalone Performance:

  • Revenue: ₹13,061 million (21.6% increase)
  • Profit After Tax: ₹1,882 million (12.3% increase)
  • EPS Basic: ₹11.83

IPO and Capital Structure Changes

The company completed its Initial Public Offering on October 16, 2025, comprising:

  • Fresh issue: 10,313,058 equity shares raising ₹5,000 million
  • Offer for sale: 18,092,783 equity shares for ₹8,775 million
  • Promoter holding reduced from 83.03% to 59.55%
  • Net proceeds received: ₹4,713 million (net of ₹287 million expenses)
  • Utilization: ₹2,646 million debt repayment, ₹590 million inorganic growth
  • Unutilized amount: ₹1,476 million as of March 31, 2026

Strategic Acquisitions and Expansion

Key Acquisitions:

  • Arinna Lifesciences Limited: Acquired 85% stake for ₹1,759 million (completed April 2026)
  • Alkem's Pithampur Facility: Manufacturing site for oral solids including steroids and oncology products
  • AimRx 3PL LLC: US-based pharmaceutical logistics provider licensed across 45 states
  • Validus Pharmaceuticals LLC: New Jersey-based marketer specializing in CNS and CVS therapies
  • Meditab Specialities: Oral liquids facility in Satara, Maharashtra

Manufacturing and R&D Capabilities

Manufacturing Facilities: 3 sites (Ambernath, Satara, Pithampur) with USFDA, MHRA UK, TGA Australia approvals

R&D Centers: 2 facilities (Thane, Maharashtra and Ontario, Canada) with 240+ professionals

Product Pipeline: 76 active ANDAs, 8 active NDAs, 24 products under USFDA review

Commercialized Products: 77 products with 12 new approvals in FY26

Corporate Actions and Governance

27th Annual General Meeting: Scheduled for August 26, 2026 via video conferencing

Dividend: Board recommended final dividend of ₹1.50 per equity share (150%) for FY26

ESOP: Allotted 652,390 equity shares under Employee Stock Option Scheme 2022

Proposed ESOP 2026: New plan for up to 2,484,415 options for employees and subsidiaries

Merger Proposal: Planned merger with wholly owned subsidiary KIA Health Tech Private Limited

Risk Factors and Challenges

  • Revenue concentration: Top 5 customers contributed 72% of revenue
  • Foreign currency exchange risk exposure
  • Ongoing tax disputes amounting to ₹184 million under various appeals
  • GST authorities conducted search proceedings in January 2026 (no material discrepancies identified)
  • Interest rate sensitivity: 100bp change affects profit/loss by ₹24 million

Operational Metrics and Subsidiaries

Employee Strength: 1,303 employees with 17% women representation

Subsidiaries: AdvaGen Holdings Inc, Rubicon Research Canada Limited, Validus Pharmaceutical LLC, Kia Health Tech Pvt Ltd

Geographical Revenue: USA (99.1%), India (0.4%), Others (0.5%)

Trade Receivables: ₹5,095 million (increase from ₹3,246 million)

Trade Payables: ₹3,775 million (increase from ₹2,391 million)

Regulatory Compliance and Audits

Auditor: Deloitte Haskins & Sells LLP provided unqualified opinion

Secretarial Audit: Clean report from BNP & Associates with no qualifications

Internal Controls: Adequate internal financial controls established and operating effectively

Compliance: Full compliance with SEBI Listing Regulations and Companies Act requirements

Forward-looking Strategy

The company continues to focus on strategic acquisitions, R&D investment (76 active ANDAs), and market expansion while maintaining strong corporate governance standards. The successful IPO has strengthened the balance sheet with reduced debt and enhanced financial flexibility for future growth initiatives.